Patents by Inventor Sam LINDGREN

Sam LINDGREN has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHODS FOR TREATING LIVER DISORDERS USING FXR AGONISTS
    Publication number: 20220313677
    Abstract: The invention provides methods for modulating the activity of farnesoid X receptors (FXRs) using specific FXR agonists, in particular for treating or preventing liver diseases.
    Type: Application
    Filed: April 26, 2022
    Publication date: October 6, 2022
    Inventors: Michael BADMAN, Jin CHEN, Bryan LAFFITTE, Sam LINDGREN
  • Methods for treating liver disorders using FXR agonists
    Patent number: 11344540
    Abstract: The invention provides methods for modulating the activity of farnesoid X receptors (FXRs) using specific FXR agonists, in particular for treating or preventing liver diseases.
    Type: Grant
    Filed: February 20, 2017
    Date of Patent: May 31, 2022
    Assignee: Novartis AG
    Inventors: Bryan Laffitte, Michael Badman, Jin Chen, Sam Lindgren
  • Methods for treating gastrointestinal disorders using FXR agonists
    Patent number: 11229634
    Abstract: The invention provides methods for modulating the activity of farnesoid X receptors (FXRs) using specific FXR agonists, in particular for treating or preventing liver and gastrointestinal diseases.
    Type: Grant
    Filed: February 17, 2017
    Date of Patent: January 25, 2022
    Assignee: Novartis AG
    Inventors: Bryan Laffitte, Michael Badman, Jin Chen, Sam Lindgren
  • METHODS FOR TREATING LIVER DISORDERS USING FXR AGONISTS
    Publication number: 20210386729
    Abstract: The invention provides methods for modulating the activity of farnesoid X receptors (FXRs) using specific FXR agonists, in particular for treating or preventing liver diseases and disorders. In one embodiment, the invention provides a pharmaceutical unit dosage form composition, comprising a compound of Formula (I) or a stereoisomer, enantiomer or pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: July 23, 2021
    Publication date: December 16, 2021
    Inventors: Michael BADMAN, Jin CHEN, Bryan LAFFITTE, Sam LINDGREN
  • Methods for treating liver disorders using FXR agonists
    Patent number: 11110083
    Abstract: The invention provides methods for modulating the activity of farnesoid X receptors (FXRs) using specific FXR agonists, in particular for treating or preventing liver diseases and disorders.
    Type: Grant
    Filed: February 20, 2017
    Date of Patent: September 7, 2021
    Assignee: Novartis AG
    Inventors: Bryan Laffitte, Michael Badman, Jin Chen, Sam Lindgren
  • METHODS FOR USING FXR AGONISTS
    Publication number: 20190083481
    Abstract: The invention provides methods for modulating the activity of farnesoid X receptors (FXRs) using specific FXR agonists, in particular for treating or preventing liver diseases and disorders.
    Type: Application
    Filed: February 20, 2017
    Publication date: March 21, 2019
    Inventors: Bryan LAFFITTE, Michael BADMAN, Jin CHEN, Sam LINDGREN
  • METHODS FOR USING FXR AGONISTS
    Publication number: 20190046519
    Abstract: The invention provides methods for modulating the activity of farnesoid X receptors (FXRs) using specific FXR agonists, in particular for treating or preventing liver diseases.
    Type: Application
    Filed: February 20, 2017
    Publication date: February 14, 2019
    Inventors: Bryan LAFFITTE, Michael BADMAN, Jin CHEN, Sam LINDGREN
  • METHODS FOR USING FXR AGONISTS
    Publication number: 20190046518
    Abstract: The invention provides methods for modulating the activity of farnesoid X receptors (FXRs) using specific FXR agonists, in particular for treating or preventing liver and gastrointestinal diseases.
    Type: Application
    Filed: February 17, 2017
    Publication date: February 14, 2019
    Inventors: Bryan LAFFITTE, Michael BADMAN, Jin CHEN, Sam LINDGREN
  • USE OF INHIBITORS OF THE ACTIVITY OR FUNCTION OF PI3K FOR THE TREATMENT OF PRIMARY SJOGREN'S SYNDROME
    Publication number: 20190038628
    Abstract: The invention relates to the use of 1-{(S)-3-[6-(6-methoxy-5-trifluoromethyl-pyridin-3-yl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-4-ylamino]-pyrrolidin-1-yl}-propan-1-one or pharmaceutically acceptable salts thereof for the treatment of primary Sjögren's Syndrome.
    Type: Application
    Filed: February 10, 2017
    Publication date: February 7, 2019
    Inventors: Bruno BIETH, Christoph BURKHART, Andreas CHRIST, Stefan DE BUCK, Christoph KALIS, Sam LINDGREN